The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2023 | Distinguishing and choosing between intensive and non-intensive therapies for patients with HR-MDS
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses the distinction between intensive and non-intensive treatment regimens for patients with high-risk myelodysplastic syndromes (HR-MDS), explaining which patient subsets may benefit from these therapies. Prof. Platzbecker explains that the classification of intensive versus non-intensive therapy is still largely based on tradition, and that some novel combination therapies have side effects that are typically associated with intensive approaches. Prof. Platzbecker further notes treatment regimens of varying intensity which are available for older and younger patients with HR-MDS. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
